Discover

GILD
Gilead Sciences, Inc.
125.97
1 x 120.17
1 x 132.16
bid
ask
-
0.37
0.29%
1 @ 04:00 PM
126.47 +0.50 (0.40%)
Ytd2.63%
1y12.75%
125.13
day range
127.62
107.75
52 week range
157.29
Open127.28Prev Close126.34Low125.13High127.62Mkt Cap156.40B
Vol6.19MAvg Vol7.13MEPS7.34P/E17.16Forward P/E13.04
Beta0.33Short Ratio3.02Inst. Own92.16%Dividend3.28Div Yield2.60
Ex Div Date06-15Earning08-0650-d Avg129.64200-d Avg129.831yr Est157.57

GILD News

Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
zacks.com
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend i

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
zacks.com
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05%

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
zacks.com
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer,

Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer
benzinga.com
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer

FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expandin

benzinga.com
Merck Announces FDA Approval Of KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Trodelvy, For F

U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembr

benzinga.com
Gilead Sciences Receives FDA Approval For Its Trodelvy Antibody-Dug Conjugate To Treat Adult Patient

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA)

benzinga.com
Gilead Sciences Receives European Commission's Marketing Authorization For Trodelvy As Monotherapy T

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted ma

benzinga.com
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

benzinga.com
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight

benzinga.com
Gilead Sciences New Supplemental Dug Application Accepted By FDA For Yeztugo 300-Mg Tablet; Regulato

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) acc

benzinga.com
Gilead Sciences Donates Over 2,000 Vials Of Remdesivir Intravenous Antiviral Therapy To The Republic

This donation, along with the additional supply being readied, continues the company's long-stan

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
benzinga.com
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda

benzinga.com
Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Mee

– Novel Investigational Combination Pairs Merck's Islatravir, a Next-Generation Nucleoside Analo

benzinga.com
Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (N

Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative
benzinga.com
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed

benzinga.com
Gilead Backs South Africa, Global Fund Push for HIV Prevention Drug Access

Gilead applauds the leadership of the Government of South Africa and the Global Fund for acceleratin

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
benzinga.com
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization

benzinga.com
Cencora To Support U.S. Distribution Of Gilead Subsidiary Kite's CAR T-Cell Therapies

CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company

benzinga.com
Gilead Sciences Announces Results Of Phase 3 Study In People With Primary Biliary Cholangitis That I

Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people

benzinga.com
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today